(Q28088410)

main subject

cutaneous leishmaniasis

1 reference

1 reference

B. Monge-Maillo

1

1 reference

R. Lopez-Velez

series ordinal

2

1 reference

language of work or name

1 reference

1 May 2015

1 reference

Clinical Infectious Diseases

published in

1 reference

volume

60

1 reference

issue

9

1 reference

page(s)

1398-404

1 reference

Leishmaniasis worldwide and global estimates of its incidence

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Therapeutic options for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Development of miltefosine as an oral treatment for leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Oral miltefosine for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

First case of typical Old World cutaneous leishmaniasis treated with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Treatment of imported New World cutaneous leishmaniasis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV004

21 January 2018

Identifiers

DOI

10.1093/CID/CIV004

0 references

PubMed publication ID

25601455

1 reference